Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06468202 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
A Phase 4 study of Preeclampsia and Gestational Hypertension, sponsored by Ohio State University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10,742
- Enrollment target
- 16
- Study locations
NCT06468202: Recruiting Phase 4 study of Preeclampsia and Gestational Hypertension, sponsored by Ohio State University.
NCT06468202 is a Phase 4 study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 10,742 participants, above the 902-participant average among 48 other Preeclampsia trials with a reported enrollment target (1091% higher). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06468202, a Phase 4 study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10,742 participants
- Enrollment target
- 16
- Study locations
Study Summary
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.
Primary Outcome
HDP defined as preeclampsia or antepartum gHTN based on ACOG criteria
Conditions Studied
Interventions
- DRUG Aspirin 162 mg
- DRUG Aspirin 81 mg
Study Locations (16)
California
- Cedars Sinai Medical Center - Los Angeles
- University of California, San Francisco - San Francisco
Virginia
- Inova HealthSystem - Falls Church
- Eastern Virginia Medical School - Old Dominion University - Norfolk
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- Northwestern University - Chicago
Mississippi
- University of Mississippi - Jackson
New Mexico
- University of New Mexico - Albuquerque
New York
- Columbia University - New York
North Carolina
- University of North Carolina, Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,742 participants |
| Start Date | 2024-10-18 |
| Est. Completion | 2030-02-01 |
| Phase | Phase 4 |
What NCT06468202 shows while recruiting
NCT06468202 is an interventional study that assigns participants to a tested intervention. Its 10,742 participants enrollment target places it among the larger protocols in the corpus, above the 902-participant average among 48 other Preeclampsia trials with a reported enrollment target (1091% higher).
The record links to 3 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Aspirin 162 mg is the first listed.
NCT06468202 lists 16 locations in 14 states (California, Virginia, Alabama).
Frequently Asked Questions
What is clinical trial NCT06468202 about?
NCT06468202 is a clinical study titled "Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL". The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with...
What is the current status of trial NCT06468202?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10,742 participants. The study started on 2024-10-18. Estimated completion is 2030-02-01.
What conditions does trial NCT06468202 study?
This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorders of Pregnancy.
What interventions are being tested in trial NCT06468202?
The interventions under investigation include: Aspirin 162 mg (DRUG), Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT06468202?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06468202 being conducted?
This trial has 16 study locations across Alabama, California, Illinois, Mississippi, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06468202's enrollment target sits among peer trials
10,742 2nd of 48 the highest of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AtorvaStatin Postpartum and Reduction of Cardiovascular risK
RECRUITING · Phase 4
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
RECRUITING · Phase 4
-
Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
ACTIVE NOT RECRUITING · Phase 4
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI